Progenics Pharmaceuticals (NASDAQ: [[ticker:PGNX]]) has appointed Asha Das to serve as chief medical officer. Das comes to the New York-based cancer drug developer from San Diego-based Tocagen (NASDAQ: [[ticker:TOCA]]), where she was chief medical officer. Progenics received FDA approval last July for iobenguane (Azedra), which was developed to treat tumors that form in and around the adrenal glands.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
